Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Cardiovascular Imaging Reports
Published in: Current Cardiovascular Imaging Reports 11/2014

01-11-2014 | Echocardiography (T Buck, Section Editor)

Clinical Implications from Three-dimensional Echocardiographic Analysis in Hypertrophic Cardiomyopathy

Authors: Rocio Hinojar, Jose Luis Moya Mur, Covadonga Fernández-Golfín, Jose Luis Zamorano

Published in: Current Cardiovascular Imaging Reports | Issue 11/2014

Login to get access

Abstract

Hypertrophic cardiomyopathy (HCM) is a complex and the most common inheritable cardiovascular disease. Echocardiography has numerous clinical advantages, including its availability, time and cost-efficiency, and ease of use in most patients and clinical settings. 3-dimensional echocardiography, by addressing the limitations of 2-dimensional imaging, may become the technique of choice for clinical evaluation of cardiac chambers and function in this clinical scenario. This review summarizes the role of 3D echocardiography in HCM with a focus on its diagnostic features, improving the quantification of left ventricular mass and left atrial function and the identification of the common intrinsic abnormalities of the mitral apparatus. Recent implications from 3D echocardiographic assessment and deformation analysis are also discussed including their role in the clinical diagnosis, the identification of preclinical disease in carriers of HCM mutations, and the utility in the planning and monitoring therapeutic strategies.
Literature
1.
Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58(25):e212–60.PubMedCrossRef
2.
Niimura H, Patton KK, McKenna WJ, et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation. 2002;105:446–51.PubMedCrossRef
3.
Arad M, Penas-Lado M, Monserrat L, et al. Gene mutations in apical hypertrophic cardiomyopathy. Circulation. 2005;112:2805–11.PubMedCrossRef
4.
Maron BJ, Epstein SE. Hypertrophic cardiomyopathy. Recent observations regarding the specificity of three hallmarks of the disease: asymmetric septal hypertrophy, septal disorganization and systolic anterior motion of the anterior mitral leaflet. Am J Cardiol. 1980;45:141–54.PubMedCrossRef
5.
Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778–85.PubMedCrossRef
6.
Elliott PM, GimenoBlanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357(9254):420–4.PubMedCrossRef
7.
Maron BJ, Fananapazir L. Sudden cardiac death in hypertrophic cardiomyopathy. Circulation. 1992;85:I57–63.PubMed
8.•
Chang SA, Kim HK, Lee SC, Kim EY, Hahm SH, Kwon OM, et al. Assessment of left ventricular mass in hypertrophic cardiomyopathy by real-time three-dimensional echocardiography using single-beat capture image. J Am Soc Echocardiogr. 2013;26(4):436–42. This work evaluates the accuracy and feasibility of RT3DE images to measure LV mass in patients with HCM with single-beat full-volume capture technology compared to CMR.PubMedCrossRef
9.
Bicudo LS, Tsutsui JM, Shiozaki A, Rochitte CE, Arteaga E, Mady C, et al. Value of real time three-dimensional echocardiography in patients with hypertrophic cardiomyopathy: comparison with two-dimensional echocardiography and magnetic resonance imaging. Echocardiography. 2008;25(7):717–26.PubMedCrossRef
10.
Oe H, Hozumi T, Arai K, et al. Comparison of accurate measurement of left ventricular mass in patients with hypertrophied hearts by real- time three-dimensional echocardiography versus magnetic resonance imaging. Am J Cardiol. 2005;95:1263–7.PubMedCrossRef
11.
Qi X, Cogar B, Hsiung MC, Nanda NC, Miller AP, Yelamanchili P, et al. Live/real time three- dimensional transthoracic echocardiographic assessment of left ventricular volumes, ejection fraction, and mass compared with magnetic resonance imaging. Echocardiography. 2007;24:166–73.PubMedCrossRef
12.
Jacobs LD, Salgo IS, Goonewardena S, et al. Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data. Eur Heart J. 2006;27:460–8.PubMedCrossRef
13.
Caiani EG, Corsi C, Sugeng L, MacEneaney P, Weinert L, Mor-Avi V, et al. Improved quantification of left ventricular mass based on endocardial and epicardial surface detection with real time three dimensional echocardiography. Heart. 2006;92:213–9.PubMedCrossRefPubMedCentral
14.
Yap SC, van Geuns RJ, Nemes A, Meijboom FJ, McGhie JS, Geleijnse ML, et al. Rapid and accurate measurement of LV mass by biplane real-time 3D echocardiography in patients with concentric LV hypertrophy: comparison to CMR. Eur J Echocardiogr. 2008;9:255–60.PubMed
15.•
Florian A, Masci PG, De Buck S, Aquaro GD, Claus P, Todiere G, et al. Geometric assessment of asymmetric septal hypertrophic cardiomyopathy by CMR. JACC Cardiovasc Imaging. 2012;5(7):702–11. This study provides descriptive evidence of a common spiral pattern of hypertrophy that is present in patients with asymmetrical HCM, which follows a longitudinal counterclockwise spiral trajectory.PubMedCrossRef
16.
Masci PG, De Bondt J, Bogaert J. Helical form of hypertrophic cardiomyopathy: a new entity? Eur Heart J. 2008;29:706.PubMedCrossRef
17.
Anderson RH, Ho SY, Redmann K, Sanchez-Quintana D, Lunkenheimer PP. Eur J Cardiothorac Surg. 2005;28:517–25.PubMedCrossRef
18.
Torrent-Guasp F, Kocica MJ, Corno AF, Komeda M, Carreras-Costa F, Flotats A, et al. Towards new understanding of the heart structure and function. Eur J Cardiothorac Surg. 2005;27:191–201.PubMedCrossRef
19.
Buckberg GD. Architecture must document functional evidence to explain the living rhythm. Eur J Cardiothorac Surg. 2005;27:202–9.PubMedCrossRef
20.
Caselli S, Pelliccia A, Maron M, Santini D, Puccio D, Marcantonio A, et al. Differentiation of hypertrophic cardiomyopathy from other forms of left ventricular hypertrophy by means of three-dimensional echocardiography. Am J Cardiol. 2008;102(5):616–20.PubMedCrossRef
21.
Baccouche H, Maunz M, Beck T, Gaa E, Banzhaf M, Knayer U, et al. Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography. Echocardiography. 2012;29(6):668–77.PubMedCrossRef
22.
De Isla LP, Zamorano J, Malangatana G, Martinez Quesada M, Almeria C, Rodrigo JL, et al. Morphological determinants of subaortic stenosis in hypertrophic cardiomyopathy: insights from real-time 3-dimensional echocardiography. J Am Soc Echocardiogr. 2005;18:802–4.CrossRef
23.
De Gregorio C, Recupero A, Grimaldi P, Coglitore S. Can transthoracic live 3-dimensional echocardiography improve the recognition of midventricular obliteration in hypertrophic obstructive cardiomyopathy? J Am Soc Echocardiogr. 2006;19:1190.PubMedCrossRef
24.
Fukuda S, Lever HM, Stewart WJ, Tran H, Song JM, Shin MS, et al. Diagnostic value of left ventricular outflow area in patients with hypertrophic cardiomyopathy: a real-time three-dimensional echocardiographic study. J Am Soc Echocardiogr. 2008;21(7):789–95.PubMedCrossRef
25.
Minakata K, Dearani JA, Nishimura RA, et al. Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. J Thorac Cardiovasc Surg. 2004;127:481–9.PubMedCrossRef
26.
Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation. 1998;98:2505–8.PubMedCrossRef
27.
Cavalcante JL, Barboza JS, Lever HM. Diversity of mitral valve abnormalities in obstructive hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 2012;54:517–22.PubMedCrossRef
28.
Kim DH, Handschumacher MD, Levine RA, Choi YS, Kim YJ, Yun SC, et al. In vivo measurement of mitral leaflet surface area and subvalvular geometry in patients with asymmetrical septal hypertrophy: insights into the mechanism of outflow tract obstruction. Circulation. 2010;122(13):1298–307.PubMedCrossRefPubMedCentral
29.
Maron MS, Olivotto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011;124:40–7.PubMedCrossRef
30.
Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation. 1992;85(5):1651–60.PubMedCrossRef
31.
Hwang HJ, Choi EY, Kwan J, Kim SA, Shim CY, Ha JW, et al. Dynamic change of mitral apparatus as potential cause of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Eur J Echocardiogr. 2011;12(1):19–25.PubMedCrossRef
32.
Kaple RK, Murphy RT, DiPaola LM, et al. Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes. Ann Thorac Surg. 2008;85:1527–36.e1–2.PubMedCrossRef
33.
Yu EH, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol. 2000;36:2219–25.PubMedCrossRef
34.
Serri K, Reant P, Lafitte M, et al. Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2006;47:1175–81.PubMedCrossRef
35.
Carasso S, Yang H, Woo A, et al. Systolic myocardial mechanics in hypertrophic cardiomyopathy: novel concepts and implications for clinical status. J Am Soc Echocardiogr. 2008;21:675–83.PubMedCrossRef
36.
Nagakura T, Takeuchi M, Yoshitani H, et al. Hypertrophic cardiomyopathy is associated with more severe left ventricular dyssynchrony than is hypertensive left ventricular hypertrophy. Echocardi-ography. 2007;24:677–84.CrossRef
37.
Puntmann VO, Jahnke C, Gebker R, Schnackenburg B, Fox KF, Fleck E, et al. Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. Am J Cardiol. 2010;106(7):1016–22.PubMedCrossRef
38.
Popovic ZB, Kwon DH, Mishra M, Buakhamsri A, Greenberg NL, Thamilarasan M, et al. Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging. J Am Soc Echocardiogr. 2008;21:1299–305.PubMedCrossRef
39.
Sommer A, Poulsen SH, Mogensen J, Thuesen L, Egeblad H. Left ventricular longitudinal systolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a long-term follow-up study focused on speckle tracking echocardiography. Eur J Echocardiogr. 2010;11(10):883–8.PubMedCrossRef
40.
Kansal MM, Lester SJ, Surapaneni P, Sengupta PP, Appleton CP, Ommen SR, et al. Usefulness of two-dimensional and speckle tracking echocardiography in “Gray Zone” left ventricular hypertrophy to differentiate professional football player’s heart from hypertrophic cardiomyopathy. Am J Cardiol. 2011;108:1322–6.PubMedCrossRef
41.
Garceau P, Carasso S, Woo A, Overgaard C, Schwartz L, Rakowski H. Evaluation of left ventricular relaxation and filling pressures in obstructive hypertrophic cardiomyopathy: comparison between invasive hemodynamics and two-dimensional speckle tracking. Echocardiography. 2012;29:934–42.PubMedCrossRef
42.•
Urbano-Moral JA, Rowin EJ, Maron MS, Crean A, Pandian NG. Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2014;7(1):11–9. This study evaluates the role of LV hypertrophy (measured by standard echocardiography) and LV fibrosis (measured on LGE sequences by CMR) in LV global and regional myocardial function in HCM. The extent of LV hypertrophy appears to have the most deleterious effect in myocardial functional performance.PubMedCrossRef
43.
Urbano Moral JA, Arias Godinez JA, Maron MS, Malik R, Eagan JE, Patel AR, et al. Left ventricular twist mechanics in hypertrophic cardiomyopathy assessed by three-dimensional speckle tracking echocardiography. Am J Cardiol. 2011;108(12):1788–95.PubMedCrossRef
44.
Sengupta PP, Tajik AJ, Chandrasekaran K, Khandheria BK. Twist mechanics of the left ventricle. J Am Coll Cardiol. 2008;1:366–76.CrossRef
45.
Pacileo G, Baldini L, Limongelli G, Di Salvo G, Iacomino M, Capogrosso C, et al. Prolonged left ventricular twist in cardiomyopathies: a potential link between systolic and diastolic dysfunction. Eur J Echocardiogr. 2011;12(11):841–9.PubMedCrossRef
46.
Nagueh SF, Lakkis NM, Middleton KJ, Spencer 3rd WH, Zoghbi WA, Quinones MA. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation. 1999;99:254–61.PubMedCrossRef
47.
Zhao B, Li J, Xu Y, Zhu HW, Zhi G. An initial study on left ventricular diastolic function in patients with hypertrophy cardiomyopathy using single-beat, real-time, three-dimensional echocardiography. J Geriatr Cardiol. 2012;9(3):220–7.PubMedCrossRefPubMedCentral
48.
Nistri S, Olivotto I, Betocchi S, et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am J Cardiol. 2006;98:960–5.PubMedCrossRef
49.
Woo A, Williams WG, Choi R, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation. 2005;111:2033–41.PubMedCrossRef
50.
Kühl JT, Lønborg J, Fuchs A, Andersen MJ, Vejlstrup N, Kelbæk H, et al. Assessment of left atrial volume and function: a comparative study between echocardiography, magnetic resonance imaging and multi slice computed tomography. Int J Cardiovasc Imaging. 2012;28:1061–71.PubMedCrossRef
51.
Avelar E, Durst R, Rosito GA, Thangaroopan M, Kumar S, Tournoux F, et al. Comparison of the accuracy of multidetector computed tomography versus two- dimensional echocardiography to measure left atrial volume. Am J Cardiol. 2010;106:104–9.PubMedCrossRef
52.
Keller AM, Gopal AS, King DL. Left and right atrial volumen by free hand three dimensional echocardiography: in vivo validation using magnetic resonance imaging. Eur J Echocardiogr. 2000;1:55–65.PubMedCrossRef
53.
Perez de Isla L, Feltes G, Moreno J, Martinez W, Saltijeral A, de Agustin JA, Gomez de Diego JJ, Marcos-Alberca P, Luaces M, Ferreiros J, Garcia Fernandez MA, Macaya C. Quantification of left atrial volumes using three-dimensional wall motion tracking echocardiographic technology: comparison with cardiac magnetic resonance. Eur Heart J Cardiovasc Imaging. 2014.
54.
Hage FG, Karakus G, Luke Jr WD, Suwanjutah T, Burri MV, Nanda NC, et al. Effect of alcohol-induced septal ablation on left atrial volume and ejection fraction assessed by real time three-dimensional transthoracic echocardiography in patients with hypertrophic cardiomyopathy. Echocardiography. 2008;25(7):784–9.PubMedCrossRef
55.
56.
Lakdawala NK, Thune JJ, Maron BJ, Cirino AL, Havndrup O, Bundgaard H, et al. Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy. Am J Cardiol. 2011;108:1606–13.PubMedCrossRefPubMedCentral
57.
Nagueh SF, Bachinski LL, Meyer D, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation. 2001;104:128–30.PubMedCrossRefPubMedCentral
58.
Ho CY, Sweitzer NK, McDonough B, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2002;105:2992–7.PubMedCrossRef
59.
Poutanen T, Tikanoja T, Jääskeläinen P, Jokinen E, Silvast A, Laakso M, et al. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes. Am Heart J. 2006;151(3):725.e1–9.CrossRef
60.
Aly MF, Brouwer WP, Kleijn SA, van Rossum AC, Kamp O. Three-dimensional speckle tracking echocardiography for the preclinical diagnosis of hypertrophic cardiomyopathy. Int J Cardiovasc Imaging. 2014;30(3):523–33.PubMedCrossRef
61.
Sadat K, Diddi HP, Klas B, Asaad AH, Cekirdekçi E, Sungur A, et al. Live/Real Time Three-Dimensional Transesophageal Echocardiographic Assessment of Ventricular Septal Volume and Mass before and after Myectomy in Hypertrophic Cardiomyopathy. Echocardiography. 2013;30(10):1227–31.PubMedCrossRef
62.
Qin JX, Shiota T, Asher CR, et al. Usefulness of real-time three- dimensional echocardiography for evaluation of myectomy in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2004;94:964–6.PubMedCrossRef
63.
Sitges M, Qin JX, Lever HM, et al. Evaluation of left ventricular outflow tract area after septal reduction in obstructive hypertrophic cardiomyopathy: a real-time 3-dimensional echocardiographic study. Am Heart J. 2005;150:852–8.PubMedCrossRef
64.
Moya Mur JL, Salido Tahoces L, Mestre Barcelo JL, Fernandez Golfín C, Zamorano Gómez JL. Three-dimensional contrast echocardiography-guided alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2014;15(2):226.PubMedCrossRef
65.
Bogunovic N, van Buuren F, Horstkotte D, Faber L. Rapid Visualization of PTSMA Target Area by Real Time 3D Myocardial Contrast Echocardiography. Echocardiography. 2014.
66.
Moya Mur JL, Salido Tahoces L, Mestre Barcelo JL, Rodriguez Muñoz D, Hernández R, Fernandez Golfín C, et al. Alcohol septal ablation in hypertrhrophic cardiomyopathy. 3D contrast echocardiography allows localization and quantification of the extension of intraprocedural vascular recruitment. Int J Cardiol. 2014. doi:10.​1016/​j.​ijcard.​2014.​04.​080.PubMed
Metadata
Title
Clinical Implications from Three-dimensional Echocardiographic Analysis in Hypertrophic Cardiomyopathy
Authors
Rocio Hinojar
Jose Luis Moya Mur
Covadonga Fernández-Golfín
Jose Luis Zamorano
Publication date
01-11-2014
Publisher
Springer US
Published in
Current Cardiovascular Imaging Reports / Issue 11/2014
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-014-9294-9

Other articles of this Issue 11/2014

Current Cardiovascular Imaging Reports 11/2014 Go to the issue

Echocardiography (T Buck, Section Editor)

Echocardiographic Deformation Imaging for the Assessment of Left Ventricular Function: Clinical Implications and Perspectives— Update 2014

Cardiac Computed Tomography (S Achenbach and T Villines, Section Editor)

Cardiac CT Prior to Left Atrial Appendage Closure Device Implantation and Percutaneous Mitral Valve Interventions

Echocardiography (T Buck, Section Editor)

Real-Time Three-Dimensional Echocardiographic Flow Quantification in Valvular Heart Disease

Echocardiography (T Buck, Section Editor)

Quantitative Analysis of Aortic Valve Stenosis and Aortic Root Dimensions by Three-Dimensional Echocardiography in Patients Scheduled for Transcutaneous Aortic Valve Implantation

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits